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ImmunohistochemistryMutations in LRRK2 are the most common genetic cause of Parkinson's disease (PD). The most prevalent
LRRK2 mutation is the G2019S coding change, located in the kinase domain of this complex multi-domain
protein. The majority of G2019S autopsy cases feature typical Lewy Body pathology with a clinical phenotype
almost indistinguishable from idiopathic PD (iPD). Here we have investigated the biochemical characteristics
of α-synuclein in G2019S LRRK2 PD post-mortem material, in comparison to pathology-matched iPD. Immu-
nohistochemistry with pS129 α-synuclein antibody showed that the medulla is heavily affected with pathol-
ogy in G2019S PD whilst the basal ganglia (BG), limbic and frontal cortical regions demonstrated comparable
pathology scores between G2019S PD and iPD. Signiﬁcantly lower levels of the highly aggregated α-synuclein
species in urea–SDS fractions were observed in G2019S cases compared to iPD in the BG and limbic cortex.
Our data, albeit from a small number of cases, highlight a difference in the biochemical properties of aggre-
gated α-synuclein in G2019S linked PD compared to iPD, despite a similar histopathological presentation.
This divergence in solubility is most notable in the basal ganglia, a region that is affected preclinically and
is damaged before overt dopaminergic cell death.
© 2013 The Authors. Published by Elsevier Inc. All rights reserved.Introduction
Mutations in the LRRK2 gene, ﬁrst identiﬁed in 2004 (Paisan-Ruiz
et al., 2004; Zimprich et al., 2004), are one of the most common
genetic causes of PD (Tan and Skipper, 2007). Recent genome wide
association studies have also identiﬁed LRRK2 as a risk locus for
idiopathic PD (iPD) (Nalls et al., 2011), highlighting this gene as one
of the key genetic factors in the aetiopathogenesis of PD. LRRK2
codes for a large multidomain protein harbouring several putative
protein–protein interaction motifs, along with a GTPase and a kinase
domain (Mata et al., 2006). Mutations that segregate with disease are
restricted to the enzymatic core of the protein, suggesting that theerms of the Creative Commons
which permits non-commercial
d the original author and source
eurological Studies UCL Institute
ndopadhyay).
irect.com).
blished by Elsevier Inc. All rights rekinase and GTPase activities of LRRK2 are linked to this protein's role
in PD (Ross et al., 2011). The G2019S mutation lies in the kinase
domain and is the most common cause of autosomal dominant PD,
accounting for up to 2% of all PD cases (Martin et al., 2010). Patients
harbouring LRRK2 mutations manifest clinical features almost indistin-
guishable from the idiopathic form of the disease (Healy et al., 2008).
The neuropathology associated with LRRK2mutations, however, is var-
iable and encompasses α-synuclein positive Lewy bodies (LBs), tau
positive inclusions, TDP-43 aggregates, ubiquitin only inclusions and
pure nigral cell loss with no inclusions (Wider et al., 2010). Nonethe-
less, nigral cell loss is the common pathological feature amongst all of
the LRRK2 mutation cases, with the majority of cases (including those
with the G2019S mutation) displaying α-synuclein positive pathology
(Cookson et al., 2008; Poulopoulos et al., 2012).
The G2019S mutation is thought to increase LRRK2 kinase activity,
as documented by augmented autophosphorylation and phosphoryla-
tion of other generic targets (Greggio and Cookson, 2009; Greggio et
al., 2006; Smith et al., 2005; Smith et al., 2006; West et al., 2005).
The pleomorphic pathology associated with the G2019S mutation
suggests that LRRK2 may act upstream of α-synuclein, tau and
TDP-43, underlining the need to identify signalling pathways linkedserved.
Table 1
Selective demographic data of cases studied. PMD: post-mortem delay (h).
Case Sex Age
(yrs)
PMD
(h)
pH Disease duration
(yrs)
α-Synuclein
pathology
G2019S 1 F 80 44.4 6 28 Limbic
G2019S 2 F 81 15 6.53 16 Limbic
G2019S 3 F 84 32.2 5.79 N/A Limbic
G2019S 4 F 72 24.55 6.1 15 Limbic
G2019S 5 (FCx) M 85 1.66 N/A 11 Limbic
iPD 1 F 69 52.5 6.2 14 Limbic
iPD 2 M 70 61.2 6.29 12 Limbic
iPD 3 F 87 47.45 6.62 13 Limbic
iPD 4 M 75 48 6.0 17 Limbic
iPD 5 F 88 11.3 6.38 10 Limbic
Control 1 F 85 37 6.4 – –
Control 2 M 93 112 5.86 – –
Control 3 F 91 98.5 6.26 – –
Control 4 M 87 36 6.1 – –
Control 5 F 68 41.5 5.98 – –
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interacting proteins for LRRK2 have been proposed, including
α-synuclein, 4E-BP1, moesin, tubulin, dvl, lrp6 and ArfGAP1
(Berwick and Harvey, 2012; Gandhi et al., 2008; Imai et al., 2008;
Jaleel et al., 2007; Qing et al., 2009; Sancho et al., 2009; Stafa et al.,
2012). The physiological relevance of the majority of these interac-
tions are yet to be determined whilst some may have limited impli-
cations in vivo (Trancikova et al., 2012). In transgenic mice, an
interaction between LRRK2 and α-synuclein has been suggested by
Lin et al. (2009) who demonstrated that the presence of excess WT/
G2019S LRRK2 can accelerate the progression of A53T α-synuclein
mediated neuropathology in a CAMKII driven inducible model, and
promote the formation of high molecular weight α-synuclein
aggregates — with ablation of LRRK2 acting to modulate pathology.
Intriguingly, this study reported a decrease in phosphorylation of
α-synuclein upon over-expression of the G2019S mutation. In
contrast, further studies using the hind-brain selective prion protein
promoter to drive LRRK2 expression failed to detect an effect on
α-synuclein pathology in A53T transgenic mice, and thus not
supporting a pathophysiological interaction in vivo whilst high
LRRK2 levels improved motor skills in a mouse model and was insuf-
ﬁcient to drive neuronal α-synucleinopathy (Daher et al., 2012;
Herzig et al., 2012; Lin et al., 2009). Interestingly, however, accumula-
tion of α-synuclein monomers and high molecular weight species
alongwith development ofα-synuclein inclusions have been reported
in the kidneys of LRRK2 KO mice with age (Tong et al., 2009).
Further genetic evidence that LRRK2 and SNCA (the gene coding
for α-synuclein) are linked comes from a recent study demonstrating
that a polymorphism in SNCA is associated with lower age of onset for
LRRK2 patients (Botta-Orﬁla et al., 2012). Furthermore, a current
study has shown lower levels of α-synuclein in leukocytes of patients
with G2019S LRRK2 mutation (Pchelina et al., 2011) and that
α-synuclein and LRRK2 may be expressed synergistically in rodents
(Westerlund et al., 2008). In addition, our group has shown that
α-synuclein pathology affected regions in iPD and G2019S PD express
lower levels of LRRK2 transcript compared to controls, in the absence
of an effect on global gene expression levels (Devine et al., 2011;
Sharma et al., 2011). However, the nature of the interaction between
LRRK2 and α-synuclein, two of the most important autosomal domi-
nant players in genetic Parkinson's, remains ambiguous.
At the Queen Square Brain Bank, we hold four G2019S cases that
have α-synuclein positive LB pathology. We sought to explore the
pathological and biochemical characteristics of α-synuclein in the
presence of thismutation in LRRK2. The aim of this studywas to inves-
tigate the morphological distribution and solubility of α-synuclein in
the G2019S cases compared to iPD cases, matched for pathology, and
control cases. We show that, despite extensive LB pathology, highly
aggregated α-synuclein species are largely absent in the G2019S PD
cases examined.
Methods
Case details and tissue collection
Post-mortem human brain tissues from 14 cases were obtained
from the Queen Square Brain Bank collection and one G2019S case
was obtained from the Sun Health Research Institute, USA. Appropri-
ate consent was obtained in all cases and approval for this study was
granted by the local Research Ethics Committee. The 4 G2019S PD
cases in our brain bank were classiﬁed neuropathologically (by
consultant neuropathologists) as the limbic sub-type for α-synuclein
pathology according to McKeith consensus criteria (McKeith et al.,
2005). The 5th G2019S case, from Sun Health, also harboured the lim-
bic subtype of α-synuclein pathology. The routine α-synuclein immu-
nohistochemistry is done using pre-treatment with formic acid
(10 min) and pressure cooking in citrate buffer at pH 6.0 to exposeantigenic sites. The primary antibody used is against α-synuclein
(Novocastra) at a dilution of 1:75. The iPD cases chosenwere pathology
matched, whilst the controls had no signs of any signiﬁcant neuropa-
thology and did not suffer from any neurological disease. Clinical phe-
notype of the G2019S and iPD cohorts were that of slow progressive
parkinsonism with good levodopa response. Flash frozen tissue was
obtained from the basal ganglia (caudate and putamen), limbic (ento-
rhinal cortex) cortex and frontal cortex of these cases (care was taken
to dissect the correct anatomical regions for biochemical analysis).
Immunohistochemistry (IH) on formalin ﬁxed sections for phospho-
α-synuclein was performed on sections of medulla, substantia nigra,
basal ganglia, entorhinal cortex, cingulate gyrus and frontal cortex
where available. Restricted demographics of the cases are presented
in Table 1.
Immunohistochemistry
Immunohistochemistry (IH) was performed on formalin ﬁxed
parafﬁn embedded 8 μm sections from a number of regions namely,
medulla, substantia nigra, basal ganglia, entorhinal cortex, cingulate
gyrus, and frontal cortex from four G2019S, four iPD and four control
cases as listed in Table 2. The cases and controls were stained at the
same time. Sections were dewaxed, and quenched for endogenous
peroxidase activity using methanol and 0.3% H2O2. The sections were
pre-treated with proteinase K (Dako) for 15 min to expose antigenic
sites. Following thorough washes, non-speciﬁc binding on sections
was blocked for 1 h with 10% non-fat milk in 1× PBS. The sections
were then incubated with anti-phospho-Ser129-α-synuclein (Mono-
clonal, a kind gift of Dr John Anderson, Elan Pharmaceuticals) 1: 2000
for 1 h at room temperature. Following thorough washes, the sections
were sequentially incubated with biotinylated secondary antibody
(anti-mouse, Vector Laboratories) at 1:200, followed by treatment
with avidin-biotin peroxidase complex (ABC, Vector Laboratories) for
30 min each. Following a series of washes in 1× PBS, IH was visualised
using hydrogen peroxide-activated diaminobenzidine (Sigma). The
sections were then dehydrated in graded ethanol (70–100%) followed
by xylene and then mounted in DPX (VWR). The pS129 antibody has
been extensively characterised for immunoblots and immunohisto-
chemistry (Anderson et al., 2006; Guerreiro et al., 2012).
Phospho-α-synuclein scores
The severity of pS129 α-synuclein scores was assessed indepen-
dently by two researchers based on a 3 point scoring system at ×20
objective. Score: where + corresponds to 1 LB, sparse Lewy neurites
(LNs) and dot like structures, score ++ was given when the number
Table 2
Immunohistochemistry scores for phosphorylated α-synuclein depositions in the var-
ious regions studied. Severity of pS129 α-synuclein positive pathology from different
regions of G2019S and idiopathic PD cases was scored by two researchers indepen-
dently on a three point scoring system where “+”, “++”, “+++” indicate mild, mod-
erate and severe pathologies respectively. N/A indicates section not available for
staining. DMN = dorsal motor nucleus of the vagus.
Case DMN Midbrain Striatum Entorhinal
cortex
Cingulate
gyrus
Frontal
cortex
G2019S 1 +++ +++ +++ +++ N/A +
G2029S 2 +++ +++ ++ N/A N/A +
G2019S 3 +++ ++ +++ ++ + +
G2019S 4 N/A ++ ++ +++ + +
iPD 1 ++ +++ ++ +++ + +
iPD 2 ++ +++ ++ +++ + +
iPD 3 +++ +++ ++ ++ + +
iPD 4 ++ ++ +++ ++ + +
185A. Mamais et al. / Neurobiology of Disease 58 (2013) 183–190of lesions corresponded to between 2–10 LBs and the presence of
mild numbers of neurites, +++ score was given when the number
of LBs were greater than 10 and also containing numerous LNs and
dot like structures. Independent data scores were compared and con-
sensus results derived.Differential ultracentifugation and fractionation
10% (w/v) homogenates were prepared from 1 g tissue from the
basal ganglia, limbic cortex and frontal cortex regions in homogenisa-
tion buffer [20 mM Tris–HCl pH 7.4, 150 mMNaCl, 1× protease inhibi-
tor cocktail (EDTA free; ROCHE) and 1× phosphatase inhibitor cocktail
(ROCHE)] with the aid of a mechanical homogeniser, and cleared by
centrifugation at 1000 g for 5 min at 4 °C. The supernatant was desig-
nated as cleared homogenate. The cleared homogenates were
centrifuged at 100,000 g for 1 h at 4 °C and the supernatant was la-
belled as the TBS-soluble fraction. The pelletwaswashed twicewith ho-
mogenisation buffer, resuspended in 2.5 ml homogenisation buffer
with 5% (w/v) SDS, sonicated (5 × 20 s) and centrifuged at 100,000 g
for 30 min at 16 °C. The supernatant was designated as the SDS-
soluble fraction. The pellet was rinsed twice with homogenisation buff-
er with 5% (w/v) SDS and re-suspended by sonication in 50 μl homoge-
nisation buffer containing 8% (w/v) SDS and 8 M urea, sonicated and
designated as the urea-soluble fraction. The protein concentrations
were calculated by BCA protein assay (Pierce).Western blotting
30 μg (for cleared homogenates, TBS and SDS soluble fractions)
and 6 μg (for the urea-soluble fractions) of each samplewere analysed
by immunoblot using 12% polyacrylamide gels (BIO-RAD). After trans-
fer to PVDF membranes they were blocked in PBS, 0.1% Tween X-100,
5% BSA and an antibody againstα-synuclein (BD Transduction Labora-
tories) was used at 1:750 dilution in overnight incubation at 4 °C in
PBS, 0.1% Tween X-100, 1% BSA. Secondary HRP-conjugated antibody
(Santa Cruz) was used at 1:2000 dilution for 1 h at room temperature.
For the dot-blot, 3 μg of the urea-soluble fractions were blotted on
activated PVDF membrane and were left to air-dry, followed by a
standard western blot processing. For the western blots the bands
were quantitated using the NIH ImageJ software and the graphs and
statistics were generated in GraphPad Prism. The band intensities
were normalised to an internal control for comparison across groups
and subsequently expressed as relative ratios of the monomeric
synuclein over the β-actin. The statistical tests used were Mann–
Whitney U test, ANOVA (Bonferroni correction) and ANCOVA as
indicated in the text.Results
Phospho-S129 α-synuclein pathology in G2019S and idiopathic PD
The iPD cases chosen from the QSBB archive were matched for
α-synuclein pathology with the G2019S LRRK2 mutation cases and
all were classiﬁed as having limbic sub-type distribution according
to the McKeith criteria for classiﬁcation of LBs (McKeith et al.,
2005). The α-synuclein pathology for three of our G2019S cases has
been discussed brieﬂy by Gilks et al. (2005).
Immunohistochemical analysis of pS129 α-synuclein revealed
staining for LBs and LNs in sites of LB predilection namely medulla,
substantia nigra, basal ganglia, entorhinal cortex and frontal cortex
in both the G2019S and iPD (Fig. 1). The pS129 α-synuclein immuno-
histochemistry was semi-quantitatively assessed for severity of
pathology in the G2019S and idiopathic PD. Data are summarised in
Table 2. The scoring pattern is consistent with the cases fulﬁlling
the criteria for limbic sub-type for α-synuclein pathology with higher
scores noted in the amygdala and entorhinal cortex and only few LBs
were noted in the frontal cortex. The pS129 α-synuclein antibody
stained typical LBs, small and large neurites, whilst also several
dot-like positive structures were noted in the neuropil of all of the re-
gions examined. It is noteworthy that 3 G2019S cases where medulla
sections were available had severe pathology in the dorsal motor
nucleus of the vagus (DMN). The control cases used in this study
had no pS129 α-synuclein positive inclusions (Fig. 1).
α-Synuclein solubility in G2019S brains
The levels and solubility of the monomeric α-synuclein species
were investigated in basal ganglia, limbic cortex and frontal cortex
tissue from G2019S, iPD and control brains. Cleared homogenates
were prepared from the tissues followed by fractionation to produce
TBS-soluble, SDS-soluble and urea-soluble fractions. A trend towards
an increase in monomeric α-synuclein was observed across the PD
spectrum compared to controls in basal ganglia cleared homogenates,
with the G2019S being signiﬁcantly higher than controls in the limbic
cortex (Figs. 2A, B, C) (p b 0.05; Mann–Whitney U test). In both
TBS-soluble and SDS-soluble fractions, higher levels of monomeric
α-synuclein were observed in iPD versus controls in the basal ganglia,
which reﬂects and follows the similar trend observed in basal ganglia
homogenates (Figs. 2D, G) (for basal ganglia TBS iPD: control,
p b 0.05; Mann–Whitney U). The G2019S also showed higher
TBS-soluble α-synuclein compared to controls but the G2019S
SDS-soluble levels did not follow the trend of the iPD cases, rather
they were comparable to the controls (for TBS G2019S: controls,
p b 0.05; Mann–Whitney U) (Figs. 2D, G). These effects in the distri-
bution of monomeric α-synuclein species across soluble fractions
were largely minimised in the frontal cortex, which is not affected
by Lewy Body pathology (Figs. 2F, I).
The most signiﬁcant observation on a possible effect of a mutant
LRRK2 genotype on α-synuclein biochemistry came from looking at
the urea-soluble fractions of these cases, which represent highly
insoluble species that are insoluble in 5% SDS containing buffer. In
the urea-soluble fractions, detection of α-synuclein was largely
absent in the G2019S and control cases whilst highly aggregated
α-synuclein species were detected in the majority of the iPD samples
from the basal ganglia and the limbic cortex (Figs. 3A, B). The single
band detected in the G2019S urea-soluble fractions was indicative
of monomeric α-synuclein running between the 14 kDa and 19 kDa
protein standards. To address the possibility that the α-synuclein
species in the urea-fraction of G2019S are in fact insoluble in urea
and therefore not separated by SDS-PAGE, a dot-blot experiment
was performed where equal amounts of urea-soluble fractions were
blotted and probed for α-synuclein (Fig. 3C). This indicated signiﬁ-
cantly lower levels of α-synuclein species in the urea-fraction of
Fig. 1. Immunohistochemistry of pS129 α-synuclein inclusions in G2019S, iPD and control post-mortem brains. Formalin ﬁxed sections were stained for pS129 α-synuclein. All of
our G2019S cases are categorised as the limbic subtype of α-synuclein pathology, according to the McKeith criteria (McKeith et al., 2005). The regions examined were medulla,
substantia nigra, basal ganglia (putamen), entorhinal cortex and frontal cortex. The DMN (dorsal motor nucleus of vagus) of the G2019S cases tended to have higher pS129
α-synuclein inclusions whilst comparable pS129 α-synuclein staining is observed in inclusion bodies in G2019S and idiopathic PD in the nigra, limbic cortex and frontal cortex.
Scale bar correspond to10 μm in A, B, E, F, H, K, and L and 20 μm in C, D, G, I, J, M, N, and O.
186 A. Mamais et al. / Neurobiology of Disease 58 (2013) 183–190G2019S compared to iPD, whilst the controls did not show any
detectable positivity for the protein.
The G2019S and iPD cases had comparable post-mortem delays
(PMDs) whilst the controls showed a wider spread of values but not
statistically signiﬁcant divergence (Fig. S2A). A possible effect of
PMD on protein stability that could skew the results obtained by the
urea-soluble fractions was investigated by analysis of covariance.
Adding PMD as the covariate on the urea-soluble α-synuclein data
showed that the G2019S cases have statistically signiﬁcant lower
α-synuclein levels compared to the iPD group even after controlling
for a possible effect of PMD (ANCOVA; basal ganglia: F2,10 = 19.37,
p b 0.001; limbic cortex: F2,10 = 17.12, p = 0.001). In fact, a linear
regression plot of the urea-soluble data for iPD over PMD further sug-
gests that the levels of α-synuclein in this fraction do not covary with
PMD (Fig. S2E). Linear regression analyses of monomeric α-synuclein
levels over PMD were performed for all data to investigate a possible
effect of PMD on the levels of α-synuclein across the different
fractions. As depicted in Fig. S2B, there is a slight trend of negative
correlation in the α-synuclein levels in homogenates over PMD, but
this is not signiﬁcant (r2 = 0.041, p = 0.54). Similar results were
obtained from the SDS and TBS soluble data, revealing non-
signiﬁcant correlation to PMD (Figs. S2C, D).Discussion
The most important ﬁnding of this study is the divergent solubility
properties observed for α-synuclein in G2019S PD post-mortem brains
compared to iPD cases, despite a similar distribution of α-synuclein pa-
thology. Signiﬁcantly, differential ultracentifugation followed by immu-
noblot analysis revealed that α-synuclein species were largely absent
in the urea soluble fraction in G2019S PD. To our knowledge, this is the
ﬁrst detailed study comparing solubility of α-synuclein in LRRK2
G2019S and pathology matched idiopathic PD cases as an attempt to
directly dissect the nature of the LRRK2-synuclein interplay in post-
mortem familial PD tissue.
A key factor facilitating this study is that the iPD cohort has been care-
fullymatched to the G2019S cases in terms of pathology progression and
severity, namely the limbic subtype according to McKeith et al. (2005),
and this allows us to interpret any differences seen in α-synuclein bio-
chemistry between these two series as a consequence of LRRK2 aberrant
function. The tissue used in the biochemical analysis was dissected from
precise regions of the caudate and putamen, entorhinal and frontal cor-
tex in all the cases and in matching topology with the sections used in
histological analysis from the formalin-ﬁxed side of the donated brain,
to minimise possible variability in LB pathology.
Fig. 2. Distribution of α-synuclein monomer across cleared homogenates, TBS and SDS soluble fractions of G2019S, iPD and control post-mortem brain. The levels of α-synuclein in
cleared homogenates (A, B, C), TBS (D, E, F) and SDS (G, H, I) soluble fractions of three G2019S, iPD and control brain regions were examined. A trend of increased solubility of
α-synuclein in G2019S compared to that in iPD is observed in basal ganglia (D, G), that is not evident in the less pathologically affected areas of the cortex (E, F, H, I). [Mann–
Whitney U test: *p b 0.05].
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pS129 α-synuclein in LBs and LNs in all the disease cases in sites of
LB predilection. This is consistent with earlier data examining iPD
cases (Anderson et al., 2006; Fujiwara et al., 2002). We also demon-
strate abundant pS129 α-synuclein pathology in the medulla, a re-
gion that is affected early in disease (Braak et al., 2003; Kingsbury
et al., 2010) suggesting that phosphorylation of α-synuclein is an
early event in disease pathogenesis and might be involved in disease
propagation (Kondo et al., 2011; Li et al., 2008). The DMN of the
G2019S cases were more severely affected compared to the iPD co-
hort. The limbic cortex (entorhinal cortex) displayed substantial
pS129 α-synuclein pathology in all the PD cases examined, whilst
fairly mild involvement of the frontal cortex was apparent in these
cases (Fig. 1; Table 2). These results are consistent with the G2019Sand iPD cases being of the limbic category for α-synuclein pathology.
The pS129 α-synuclein dot-like pathology observed in the neuropil in
the disease cases is likely to represent synaptic pathology (Muntane
et al., 2008). The α-synuclein antibodies used in this study have
been previously characterised for immunohistochemistry and immu-
noblots (Anderson et al., 2006; Guerreiro et al., 2012; Miller et al.,
2004). As previously described, the pS129 α-synuclein antibody
necessitated the use of proteinase-K to reveal antigenic sites. Conse-
quently, our control cases were devoid of any pS129 α-synuclein
immunoreactivity.
We used brain tissue from the basal ganglia, limbic cortex (ento-
rhinal cortex) and frontal cortex to generate cleared homogenates
followed by serial fractionation into TBS, SDS and urea-soluble frac-
tions and investigated the distribution of α-synuclein across these
Fig. 3. Divergence of G2019S PD brains in levels of highly aggregated urea-soluble α-synuclein species. The urea-soluble fractions of basal ganglia (A) and limbic cortex (B) of
G2019S, iPD and control brains were analysed for the presence of α-synuclein. Aggregated α-synuclein is observed in the basal ganglia and the limbic cortex of the iPD samples
following pathology severity. Very little aggregated synuclein is detected in the urea-soluble samples of the G2019S cases compared to the iPD cases. A dot-blot of
urea-fractions of the basal ganglia (C) reveals much lower levels of α-synuclein in the G2019S cases compared to that of the iPD samples, whilst no α-synuclein is detected in con-
trols. [ANOVA with Bonferroni's correction: *p b 0.01].
188 A. Mamais et al. / Neurobiology of Disease 58 (2013) 183–190fractions. Aggregated α-synuclein is the principal component of LBs
in PD (Spillantini et al., 1997). A number of studies have described
high levels of pS129 α-synuclein species in LBs, suggesting a link
to the pathological process — a notion further supported by the
increased phosphorylation at Ser129 residue reported in A53T trans-
genic mice (Anderson et al., 2006; Campbell et al., 2000; Fujiwara et
al., 2002; Wakamatsu et al., 2007). Along with hyperphosphorylation,
LB disease accompanies accumulation of signiﬁcantly higher levels of
SDS-soluble and SDS-insoluble α-synuclein species compared to con-
trol brain (Campbell et al., 2000; Zhou et al., 2011). Our data suggests
that G2019S PD may diverge from this model. We report the absence
of detectable α-synuclein species in the urea fraction (SDS insoluble)
of the basal ganglia and limbic cortex of G2019S PD cases (Figs. 3A, B).
This is further veriﬁed by dot-blot data that exclude the presence of
α-synuclein species that would be insoluble in urea and therefore
not be separated and detected by SDS-PAGE (Fig. 3C). In addition
we observe a trend of higher TBS-soluble levels of monomeric
α-synuclein compared to controls perhaps reﬂecting an increase in
cytosolic α-synuclein, along with no increase in the membrane-
enriched SDS-soluble fraction in the basal ganglia of the G2019S
samples (Figs. 2D, G). Nevertheless we detect comparably abundanthigher molecular weight α-synuclein species in G2019S and iPD
cleared homogenates from the basal ganglia (Fig. S1A), suggesting
that the differences seen in the fractions may in fact be an effect of
differential solubility properties of α-synuclein.
An important caveat of this study is that the substantia nigra, the
most relevant region to study the consequences of dopamine cell
loss, was not available from our G2019S mutation cases. The regions
studied herein are those that survived the dopaminergic system
neurodegeneration and therefore may not directly inform us as to
the pathogenic pathways involved in the substantia nigra, nonethe-
less these regions are associated with the rostrocaudal propagation
of α-synuclein disease pathology (Braak et al., 2003) and some may
be afﬂicted pre-clinically (Booij and Knol, 2007). We show extensive
α-synuclein synaptic and neuritic pathology in both G2019S and iPD
cases suggestive of synaptic degeneration (Muntane et al., 2008). The
basal ganglia have a functional link to the substantia nigra playing a
crucial role in modulating the activity of dopaminergic neurons (Lee
and Tepper, 2009). Furthermore, it has also been suggested that
dopaminergic neurodegeneration can be a result of α-synuclein
aggregate-related synaptic dysfunction through a dying back phe-
nomenon initiated in the basal ganglia (Schulz-Schaeffer, 2010).
189A. Mamais et al. / Neurobiology of Disease 58 (2013) 183–190This could highlight how the divergent biochemical properties of
pathogenic α-synuclein in the basal ganglia of G2019S PD could in
fact drive a different progression pathway to that of iPD.
The fact that the iPD and G2019S cases share comparable LB pathol-
ogy makes this divergence in α-synuclein biochemistry an intriguing
ﬁnding. A previous report suggested that the biochemical abnormalities
of α-synuclein protein might not be related with the presence of LBs in
G2019S PD cortical regions (Gomez and Ferrer, 2010). Interestingly, in
the PD-related movement disorder multiple system atrophy, which is
characterised by α-synuclein inclusions in oligodendrocytes, studies
have observed no SDS-insoluble α-synuclein species (Campbell et al.,
2001) whilst Galvin et al. reported a case of NB1A with α-synuclein in-
clusions where highly insoluble α-synuclein oligomeric species were
absent, although the protein was detected in the SDS soluble fraction
(Galvin et al, 2000). It has also been reported that themetabolomic pro-
ﬁle of G2019S LRRK2 mutants has a unique biochemical signature
(Johansen et al., 2009) further reinforcing the hypothesis that some
aspects of the pathomechanisms underlying PD may vary between
genetic and idiopathic causes (Johansen et al., 2011). A recent study
described a molecular interaction between LRRK2 and α-synuclein in
both endogenous and overexpression conditions, along with an effect
of LRRK2 levels on α-synuclein pathology, indicating that the interac-
tion between the two proteins can indeed be very complex (Guerreiro
et al., 2012).
The precise nature of the pathogenic α-synuclein species is a
matter of some debate (Cookson, 2009), however multiple lines of
enquiry suggest that some forms of aggregated, oligomeric species
are responsible for the cell loss associated withα-synuclein accumu-
lation (Vekrellis et al., 2011). A recent in vitro study has proposed
that proteinase-K-resistant oligomers that bridge the conversion of
the initially formed protein oligomers to ﬁbril formation are the dis-
ease causing forms (Cremades et al., 2012), whilst proteinase-K re-
sistant species of S129 phosphorylated α-synuclein residue are
seen in DLBs (Neumann et al., 2002). A parallel scenario may be
plausible for α-synuclein in G2019S cases where the inclusions
may represent benign protective inclusions similar to that seen in
Huntington's disease (Arrasate et al., 2004). Thus, further studies of
a proteinase-K-resistant oligomeric species may throw important
light in the case of G2019S PD.
In summary, our data suggest that signiﬁcantly low amounts of in-
soluble α-synuclein in G2019S LRRK2 could be a distinguishing fea-
ture compared to iPD. This is seen despite comparable LB pathology
in both the PD groups. The fractionation experiments performed
here did not speciﬁcally analyse α-synuclein deposited in LBs, but
rather all α-synuclein species available to be solubilised by the ex-
traction techniques. In this respect, solubility studies along with elec-
tron microscopy of α-synuclein isolated directly from LBs would shed
light on whether the divergent solubility observed in this study is a
reﬂection of altered global α-synuclein or speciﬁc to aggregated pro-
tein localised to Lewy bodies.
The major caveat to this study is the limited number of G2019S PD
post-mortem human brain material included, a reﬂection of the
low numbers of genetically deﬁned post-mortem brains available to
the scientiﬁc community. The data from the cleared homogenates,
TBS and SDS fractions show some variability between the samples
of the PD or control cases, and this reﬂects the limited statistical
power that four G2019S cases can allow for. One the other hand,
the urea fractions presented here, representing the major divergence
we see for the G2019S PD cohort compared to iPD, exhibit a robust
and uniform change in α-synuclein solubility, indicating a strong and
reproducible difference in the biochemical properties of α-synuclein.
Although brain tissue from G2019S mutation cases is rare, further rep-
lications from other cases are essential in order to fully understand
the link between LRRK2 mutations and α-synuclein inclusions. In par-
ticular, examining whether this divergence in solubility holds true for
mutations other than the G2019S, such as the R1441C, R1441G orY1699C mutations, will be critical in understanding the pathogenic
role of different LRRK2 mutations in neurodegeneration.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.nbd.2013.05.017.
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